Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 368

1.

GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.

Hitzler JK, Cheung J, Li Y, Scherer SW, Zipursky A.

Blood. 2003 Jun 1;101(11):4301-4. Epub 2003 Feb 13.

2.

Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.

Rainis L, Bercovich D, Strehl S, Teigler-Schlegel A, Stark B, Trka J, Amariglio N, Biondi A, Muler I, Rechavi G, Kempski H, Haas OA, Izraeli S.

Blood. 2003 Aug 1;102(3):981-6. Epub 2003 Mar 20.

3.

Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.

Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le Beau MM, Crispino JD.

Nat Genet. 2002 Sep;32(1):148-52. Epub 2002 Aug 12.

PMID:
12172547
4.

Natural history of GATA1 mutations in Down syndrome.

Ahmed M, Sternberg A, Hall G, Thomas A, Smith O, O'Marcaigh A, Wynn R, Stevens R, Addison M, King D, Stewart B, Gibson B, Roberts I, Vyas P.

Blood. 2004 Apr 1;103(7):2480-9. Epub 2003 Dec 4.

5.

Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: case report and review of the literature.

Sandoval C, Pine SR, Guo Q, Sastry S, Stewart J, Kronn D, Jayabose S.

Pediatr Blood Cancer. 2005 Jan;44(1):85-91. Review.

PMID:
15390279
6.

Origins of leukaemia in children with Down syndrome.

Hitzler JK, Zipursky A.

Nat Rev Cancer. 2005 Jan;5(1):11-20. Review.

PMID:
15630411
7.

Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome.

Xu G, Nagano M, Kanezaki R, Toki T, Hayashi Y, Taketani T, Taki T, Mitui T, Koike K, Kato K, Imaizumi M, Sekine I, Ikeda Y, Hanada R, Sako M, Kudo K, Kojima S, Ohneda O, Yamamoto M, Ito E.

Blood. 2003 Oct 15;102(8):2960-8. Epub 2003 Jun 19.

8.

GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.

Pine SR, Guo Q, Yin C, Jayabose S, Levendoglu-Tugal O, Ozkaynak MF, Sandoval C.

Leuk Res. 2005 Nov;29(11):1353-6.

PMID:
15916804
9.

Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis.

Mundschau G, Gurbuxani S, Gamis AS, Greene ME, Arceci RJ, Crispino JD.

Blood. 2003 Jun 1;101(11):4298-300. Epub 2003 Jan 30.

10.
11.

Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome.

Pine SR, Guo Q, Yin C, Jayabose S, Druschel CM, Sandoval C.

Blood. 2007 Sep 15;110(6):2128-31. Epub 2007 Jun 18.

12.

Acute megakaryoblastic leukemia in Down syndrome.

Hitzler JK.

Pediatr Blood Cancer. 2007 Dec;49(7 Suppl):1066-9. Review.

PMID:
17943965
13.

Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.

Cushing T, Clericuzio CL, Wilson CS, Taub JW, Ge Y, Reichard KK, Winter SS.

J Pediatr. 2006 May;148(5):687-9.

PMID:
16737888
14.

GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.

Ge Y, Stout ML, Tatman DA, Jensen TL, Buck S, Thomas RL, Ravindranath Y, Matherly LH, Taub JW.

J Natl Cancer Inst. 2005 Feb 2;97(3):226-31.

PMID:
15687366
15.

Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.

Xu G, Kato K, Toki T, Takahashi Y, Terui K, Ito E.

J Pediatr Hematol Oncol. 2006 Oct;28(10):696-8.

PMID:
17023834
16.

GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.

Carpenter E, Valverde-Garduno V, Sternberg A, Mitchell C, Roberts I, Vyas P, Vora A.

Br J Haematol. 2005 Feb;128(4):548-51.

PMID:
15686466
17.

Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.

Greene ME, Mundschau G, Wechsler J, McDevitt M, Gamis A, Karp J, Gurbuxani S, Arceci R, Crispino JD.

Blood Cells Mol Dis. 2003 Nov-Dec;31(3):351-6.

PMID:
14636651
18.

Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.

Roy A, Roberts I, Norton A, Vyas P.

Br J Haematol. 2009 Oct;147(1):3-12. doi: 10.1111/j.1365-2141.2009.07789.x. Epub 2009 Jul 6. Review.

PMID:
19594743
19.

Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1.

Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH.

Nat Genet. 2005 Jun;37(6):613-9. Epub 2005 May 15.

PMID:
15895080
20.

A leukemogenic twist for GATA1.

Look AT.

Nat Genet. 2002 Sep;32(1):83-4. Epub 2002 Aug 12. No abstract available.

PMID:
12172549

Supplemental Content

Support Center